Evidence map›Paper›PMID 36170322›Full record

ArticlePLoS neglected tropical diseases2022

Endemic mycoses in South Africa, 2010-2020: A decade-long description of laboratory-diagnosed cases and prospects for the future.

Rutendo E Mapengo, Tsidiso G Maphanga, Wayne Grayson, Nelesh P Govender

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Systemic Mycoses by Novel Onygenalean Fungal PathogensOpen forum infectious diseases · 2024
    Article
  10. Article
  11. DisseminatedFrontiers in cellular and infection microbiology · 2024
    Article
  12. Review
  13. Review
  14. Review
  15. Molecular Diagnosis of Endemic Mycoses.Journal of fungi (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Rutendo E MapengoNational Institute for Communicable Diseases (Centre for Healthcare-Associated Infections. Antimicrobial Resistance and Mycoses), a Division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0002-6014-5725
Tsidiso G MaphangaNational Institute for Communicable Diseases (Centre for Healthcare-Associated Infections. Antimicrobial Resistance and Mycoses), a Division of the National Health Laboratory Service, Johannesburg, South Africa.
Wayne GraysonAmpath National Reference Laboratory, Pretoria, South Africa.
Nelesh P GovenderNational Institute for Communicable Diseases (Centre for Healthcare-Associated Infections. Antimicrobial Resistance and Mycoses), a Division of the National Health Laboratory Service, Johannesburg, South Africa.
National Health Laboratory Service · ZA

Funding

Southern African-Pittsburgh Public Health Genomic Epidemiology Training Program (SAPPHGenE)D43TW011255 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Lee H Harrison, Anne von Gottberg · 2019 to 2026
$1.7M
FIC NIH HHS D43 TW011255
6 · The paper itself

Abstract

backgroundEmergomycosis, histoplasmosis, sporotrichosis and blastomycosis are endemic to southern Africa; the first two are AIDS-related mycoses. We described laboratory-diagnosed cases of endemic and imported mycoses in South Africa over a decade and discuss available diagnostic tools, reasons for the current under-estimation of cases and future strategies to improve case ascertainment. MATERIALS AND

methodsWe analysed electronic pathology laboratory data from all public laboratories and one large private laboratory in South Africa from 2010-2020. Diagnostic specimens processed at the national mycology reference laboratory were also included. We classified cases as proven, probable and possible based on the method of identification.

resultsWe identified 682 cases, of which 307 were proven, 279 were probable and 96 were possible. Of 307 culture-confirmed cases, 168 were identified by phenotypic methods plus sequencing, 128 by phenotypic methods alone and 11 by direct PCR. Of 279 probable cases, 176 had yeasts observed on histology, 100 had a positive Histoplasma antigen test and 3 a positive pan-dimorphic PCR test. All 96 possible cases had compatible clinical syndrome with inflammatory infiltrates on skin tissue histology. A majority of cases had an unspecified endemic mycosis (207/682, 30.4%), followed by sporotrichosis (170/682, 24.9%), emergomycosis (154/682, 22.6%), histoplasmosis (133/682, 19.5%), blastomycosis (14/682, 2.1%) and talaromycosis (4/682, 0.6%).

conclusionsThis study reports a relatively low number of cases over a decade considering an estimated large population at risk, suggesting that a substantial fraction of cases may remain undiagnosed. There is a need to increase awareness among healthcare workers and to develop rapid point-of-care diagnostic tools and make these widely accessible.

Indexed as

BlastomycosisHistoplasmosisMycosesSporotrichosisHumansLaboratoriesSouth Africa

Identifiers

PMID36170322
PMCPMC9518919
OpenAlexW4297457017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.